Generic drug maker Mylan may buy Swedish rival Meda: FT

(Reuters) - Generic drug maker Mylan Inc is looking to buy Swedish rival Meda AB in a deal that would create a $23 billion pharmaceutical company, the Financial Times reported on Thursday. The exact value of the deal is unknown but Mylan is likely to pay a "significant" premium to Meda's market value, a person familiar with the matter told the Financial Times. Meda's market valuation stood at 29.5 billion Swedish krona ($4.5 billion) at the end of trading on Thursday while Mylan's market value was $18.5 billion. Pennsylvania-based Mylan has appointed advisers to help it put together a deal for Meda, people familiar with the matter told the Financial Times.



via Health News Headlines - Yahoo News http://ift.tt/1fQ4A9l